MedMira, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CA58501R1029
CAD
0.07
-0.01 (-13.33%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

N/A

Shareholding

FII

N/A

DII

N/A

Promoter

N/A

iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

CAD 64 Million ()

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.65

stock-summary
Return on Equity

22.24%

stock-summary
Price to Book

-3.00

Revenue and Profits:
Net Sales:
0 Million
(Quarterly Results - Apr 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-18.75%
0%
-18.75%
6 Months
-18.75%
0%
-18.75%
1 Year
-18.75%
0%
-18.75%
2 Years
-27.78%
0%
-27.78%
3 Years
0%
0%
0.0%
4 Years
-51.85%
0%
-51.85%
5 Years
-75.0%
0%
-75.0%

MedMira, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
-2.52%
EBIT Growth (5y)
-198.08%
EBIT to Interest (avg)
-1.57
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.65
Sales to Capital Employed (avg)
-0.06
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-3.35
EV to EBIT
-24.90
EV to EBITDA
-27.99
EV to Capital Employed
-11.52
EV to Sales
86.08
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Jan 2025",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Apr 2025 is 16.67% vs 7.69% in Jan 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Apr'25",
        "Jan'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.10",
          "val2": "0.10",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-0.70",
          "val2": "-0.90",
          "chgp": "22.22%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.30",
          "val2": "0.20",
          "chgp": "50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.10",
          "chgp": "-100.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.00",
          "val2": "-1.20",
          "chgp": "16.67%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-12,761.40%",
          "val2": "-14,400.90%",
          "chgp": "163.95%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Jul'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Jul 2024 is 0.00% vs -60.00% in Jul 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Jul 2024 is -22.22% vs -50.00% in Jul 2023",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jul'24",
        "Jul'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.40",
          "val2": "0.40",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-2.10",
          "val2": "-1.60",
          "chgp": "-31.25%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.90",
          "val2": "0.90",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "0.20",
          "chgp": "-50.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-3.30",
          "val2": "-2.70",
          "chgp": "-22.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-5,872.60%",
          "val2": "-4,223.90%",
          "chgp": "-164.87%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Apr'25 - QoQstock-summary
Apr'25
Jan'25
Change(%)
Net Sales
0.10
0.10
Operating Profit (PBDIT) excl Other Income
-0.70
-0.90
22.22%
Interest
0.30
0.20
50.00%
Exceptional Items
0.00
0.10
-100.00%
Consolidate Net Profit
-1.00
-1.20
16.67%
Operating Profit Margin (Excl OI)
-12,761.40%
-14,400.90%
163.95%
USD in Million.
Net Sales

QoQ Growth in quarter ended Apr 2025 is 0.00% vs 0.00% in Jan 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Apr 2025 is 16.67% vs 7.69% in Jan 2025

Annual Results Snapshot (Consolidated) - Jul'24stock-summary
Jul'24
Jul'23
Change(%)
Net Sales
0.40
0.40
Operating Profit (PBDIT) excl Other Income
-2.10
-1.60
-31.25%
Interest
0.90
0.90
Exceptional Items
0.10
0.20
-50.00%
Consolidate Net Profit
-3.30
-2.70
-22.22%
Operating Profit Margin (Excl OI)
-5,872.60%
-4,223.90%
-164.87%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Jul 2024 is 0.00% vs -60.00% in Jul 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Jul 2024 is -22.22% vs -50.00% in Jul 2023

stock-summaryCompany CV
About MedMira, Inc. stock-summary
stock-summary
MedMira, Inc.
Pharmaceuticals & Biotechnology
MedMira Inc. is a biotechnology company. The Company is engaged in the business of research, development and manufacturing of rapid diagnostics and technologies. The Company operates through the rapid diagnostic products and services segment. The Rapid Vertical Flow (RVF) Technology platform is the basis for the Company's line of rapid tests. Its research focuses on specific areas of the diagnostics market, such as rapid, point-of-care and in vitro sectors. The RVF technology platform includes a three component system: a test cartridge, multi-function buffer and InstantGold Cap. Its technology can be applied in healthcare, research and industrial markets. It offers rapid tests for testing serum, plasma or whole blood specimens. The Company's tests are sold under brands, including Reveal, Multiplo and Miriad. The Company offers rapid tests for human immunodeficiency virus (HIV), Hepatitis B and C, and syphilis.
Company Coordinates stock-summary
Company Details
155 Chain Lake Dr.,, Suite 1 , HALIFAX NS : B3S 1B3
stock-summary
Tel: 1 902 4501588
stock-summary
Registrar Details